Ex vivo fibroblast transduction in rabbits results in long-term (>600 days) factor IX expression in a small percentage of animals

被引:17
作者
Chen, L [1 ]
Nelson, DM [1 ]
Zheng, ZL [1 ]
Morgan, RA [1 ]
机构
[1] Natl Human Genome Res Inst, Gene Transfer Technol Sect, Clin Gene Therapy Branch, NIH, Bethesda, MD 20892 USA
关键词
D O I
10.1089/hum.1998.9.16-2341
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 [微生物学]; 0836 [生物工程]; 090102 [作物遗传育种]; 100705 [微生物与生化药学];
摘要
Delivery of human factor IX to the circulation was analyzed in rabbits by ex vivo fibroblast transduction followed by subcutaneous implantation. Kinetic studies of human factor IX in rabbits demonstrated a half-life of approximately 16 hr and a volume distribution of 22%, where intraperitoneal and subcutaneous bioavailability was three- to sevenfold lower than by intravenous administration. Ex vivo retroviral transduction of autologous fibroblasts was performed on 15 animals. After subcutaneous injection of fibroblast-collagen mixtures, the expression of human factor IX in rabbit plasma was followed by ELISA, Of 15 rabbits injected, expression of human factor IX was detected in 2 animals, and expression was long term (>600 days), One animal had stable levels of human factor IX, at 20 ng/ml, while the second animal had lower and gradually decreasing levels of human factor IX, There were no gross differences in pathology at the injection sites, when comparing animals with human factor IX in plasma and those without. Immunological studies demonstrated antibody formation in response to injection mixture components (including human factor IX), but again there was no correlation with immune response and long-term factor IX production in animals. Tissues at the implantation sites were positive for factor IX DNA by PCR analysis, regardless of whether there was detectable plasma factor IX or not. Small numbers of PCR-positive cells were detected in the internal organs of the long term-expressing rabbits while similar tissues were negative in nonexpressing animals.
引用
收藏
页码:2341 / 2351
页数:11
相关论文
共 31 条
[1]
PHENOTYPIC CORRECTION OF FACTOR-IX DEFICIENCY IN SKIN FIBROBLASTS OF HEMOPHILIC DOGS [J].
AXELROD, JH ;
READ, MS ;
BRINKHOUS, KM ;
VERMA, IM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1990, 87 (13) :5173-5177
[2]
HIGH-EFFICIENCY RETROVIRAL-MEDIATED GENE-TRANSFER INTO HUMAN AND NONHUMAN PRIMATE PERIPHERAL-BLOOD LYMPHOCYTES [J].
BUNNELL, BA ;
MUUL, LM ;
DONAHUE, RE ;
BLAESE, RM ;
MORGAN, RA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (17) :7739-7743
[3]
MULTIPLE MODIFICATIONS IN CIS-ELEMENTS OF THE LONG TERMINAL REPEAT OF RETROVIRAL VECTORS LEAD TO INCREASED EXPRESSION AND DECREASED DNA METHYLATION IN EMBRYONIC CARCINOMA-CELLS [J].
CHALLITA, PM ;
SKELTON, D ;
ELKHOUEIRY, A ;
YU, XJ ;
WEINBERG, K ;
KOHN, DB .
JOURNAL OF VIROLOGY, 1995, 69 (02) :748-755
[4]
Comparison of retroviral and adeno-associated viral vectors designed to express human clotting factor IX [J].
Chen, L ;
Perlick, H ;
Morgan, RA .
HUMAN GENE THERAPY, 1997, 8 (02) :125-135
[5]
RETROVIRAL VECTORS CONTAINING CHIMERIC PROMOTER/ENHANCER ELEMENTS EXHIBIT CELL-TYPE-SPECIFIC GENE-EXPRESSION [J].
COUTURE, LA ;
MULLEN, CA ;
MORGAN, RA .
HUMAN GENE THERAPY, 1994, 5 (06) :667-677
[6]
GENE-THERAPY VIA PRIMARY MYOBLASTS - LONG-TERM EXPRESSION OF FACTOR-IX PROTEIN FOLLOWING TRANSPLANTATION INVIVO [J].
DAI, Y ;
ROMAN, M ;
NAVIAUX, RK ;
VERMA, IM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (22) :10892-10895
[7]
RETROVIRAL VECTOR-MEDIATED INVIVO EXPRESSION OF LOW-DENSITY-LIPOPROTEIN RECEPTORS IN THE WATANABE HERITABLE HYPERLIPIDEMIC RABBIT [J].
DICHEK, DA ;
BRATTHAUER, GL ;
BEG, ZH ;
ANDERSON, KD ;
NEWMAN, KD ;
ZWIEBEL, JA ;
HOEG, JM ;
ANDERSON, WF .
SOMATIC CELL AND MOLECULAR GENETICS, 1991, 17 (03) :287-301
[8]
GENE-THERAPY FOR HEMOPHILIA-B - HOST IMMUNOSUPPRESSION PROLONGS THE THERAPEUTIC EFFECT OF ADENOVIRUS-MEDIATED FACTOR-IX EXPRESSION [J].
FANG, B ;
EISENSMITH, RC ;
WANG, H ;
KAY, MA ;
CROSS, RE ;
LANDEN, CN ;
GORDON, G ;
BELLINGER, DA ;
READ, MS ;
HU, PC ;
BRINKHOUS, KM ;
WOO, SLC .
HUMAN GENE THERAPY, 1995, 6 (08) :1039-1044
[9]
TOWARDS GENE-THERAPY FOR HEMOPHILIA-B USING PRIMARY HUMAN KERATINOCYTES [J].
GERRARD, AJ ;
HUDSON, DL ;
BROWNLEE, GG ;
WATT, FM .
NATURE GENETICS, 1993, 3 (02) :180-183
[10]
SUBCUTANEOUS INJECTION OF FACTOR-IX FOR THE TREATMENT OF HEMOPHILIA-B [J].
GERRARD, AJ ;
AUSTEN, DEG ;
BROWNLEE, GG .
BRITISH JOURNAL OF HAEMATOLOGY, 1992, 81 (04) :610-613